These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12750268)

  • 1. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
    Pinthus JH; Waks T; Kaufman-Francis K; Schindler DG; Harmelin A; Kanety H; Ramon J; Eshhar Z
    Cancer Res; 2003 May; 63(10):2470-6. PubMed ID: 12750268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
    Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
    Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
    Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.
    Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
    Lee J; Wang A; Hu Q; Lu S; Dong Z
    Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
    Crittenden M; Gough M; Chester J; Kottke T; Thompson J; Ruchatz A; Clackson T; Cosset FL; Chong H; Diaz RM; Harrington K; Alvarez Vallina L; Vile R
    Cancer Res; 2003 Jun; 63(12):3173-80. PubMed ID: 12810645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells.
    Wang C; Hu W; Shen L; Dou R; Zhao S; Shan D; Yu K; Huang R; Li H
    J Immunother; 2014 Sep; 37(7):351-9. PubMed ID: 25075564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
    Pinthus JH; Waks T; Malina V; Kaufman-Francis K; Harmelin A; Aizenberg I; Kanety H; Ramon J; Eshhar Z
    J Clin Invest; 2004 Dec; 114(12):1774-81. PubMed ID: 15599402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model.
    Saika T; Kusaka N; Mouraviev V; Satoh T; Kumon H; Timme TL; Thompson TC
    Cancer Gene Ther; 2006 Jan; 13(1):91-8. PubMed ID: 16052232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
    Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
    Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.